Drug
Tradipitant clinical trials
Also written VLY-686 and LY686017.
- studies test it
- 21
- open now
- 3
- in phase 3
- 9
- first study started
- 2004
Keep track of what changes. Save the tradipitant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 10
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 2
Vanda Pharmaceuticals (17) · Eli Lilly and Company (2) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · Xiao Jing (Iris) Wang (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tradipitant is read from its arms, and is right about nine times in ten.
Testing it · 21
- Tradipitant for Functional DyspepsiaEnrolling by invitationPhase 2Xiao Jing (Iris) WangNCT05653310Written as Tradipitant
- A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseRecruitingPhase 3Vanda PharmaceuticalsNCT07446439Written as Tradipitant
- ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 InfectionEnrolling by invitationPhase 3Vanda PharmaceuticalsNCT04326426Written as Tradipitant
- Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisCompletedPhase 3Vanda PharmaceuticalsNCT06836557Written as Tradipitant
- Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisCompletedPhase 3Vanda PharmaceuticalsNCT04028492Written as Tradipitant
- Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessActive, not recruitingPhase 3Vanda PharmaceuticalsNCT06138613Written as Tradipitant
- A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseCompletedPhase 2Vanda PharmaceuticalsNCT06804603Written as Tradipitant
- Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedPhase 2Vanda PharmaceuticalsNCT03772340Written as Tradipitant
- Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessCompletedPhase 3Vanda PharmaceuticalsNCT05903924Written as Tradipitant
- Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedPhase 3Vanda PharmaceuticalsNCT04327661Written as Tradipitant
- Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisCompletedPhase 2Vanda PharmaceuticalsNCT02970968Written as VLY-686 (Tradipitant)
- Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisCompletedPhase 2Vanda PharmaceuticalsNCT02651714Written as Tradipitant
- Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic DermatitisCompletedPhase 2Vanda PharmaceuticalsNCT02004041Written as VLY-686
- Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)TerminatedPhase 3Vanda PharmaceuticalsNCT04140695Written as Tradipitant
- Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)CompletedPhase 3Vanda PharmaceuticalsNCT03568331Written as Tradipitant
- Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy VolunteersCompletedPhase 1/2Vanda PharmaceuticalsNCT04849559Written as Tradipitant
- A Study in the Treatment of Alcohol Dependence.CompletedPhase 2Eli Lilly and CompanyNCT00805441Written as LY686017
- Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy SubjectsCompletedPhase 1Vanda PharmaceuticalsNCT02621385Written as tradipitant
- Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance PCompletedPhase 1Vanda PharmaceuticalsNCT01919944Written as VLY-686
- Effect of LY686017 on Alcohol CravingCompletedPhase 2National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT00310427Written as LY686017
Codes
What other systems call tradipitant · ClinicalTrials.gg INT002158
- MeSH (NLM) C000731911tradipitantOne source NLM
- UNII (FDA) NY0COC51FITRADIPITANTConfirmed FDA, NLM, Wikidata
- Wikidata Q1798493tradipitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152707TradipitantOne source FDA
- DrugBank DB12580One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731911 | tradipitant | One source NLM |
| UNII (FDA) | NY0COC51FI | TRADIPITANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q1798493 | tradipitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152707 | Tradipitant | One source FDA |
| DrugBank | DB12580 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.